Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Mind Medicine (MindMed) Inc
Common Shares Outstanding
Mind Medicine (MindMed) Inc
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Common Shares Outstanding
$76.8m
|
CAGR 3-Years
27%
|
CAGR 5-Years
38%
|
CAGR 10-Years
23%
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Common Shares Outstanding
$370.5m
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
1%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Common Shares Outstanding
CA$368.3m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
0%
|
CAGR 10-Years
14%
|
|
|
Sundial Growers Inc
NASDAQ:SNDL
|
Common Shares Outstanding
CA$263.4m
|
CAGR 3-Years
4%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Common Shares Outstanding
$381.6m
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
25%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Common Shares Outstanding
CA$99.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
0%
|
|
Mind Medicine (MindMed) Inc
Glance View
Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2015-05-04. The firm focuses on discovering, developing and deploying psychedelic-inspired medicines and therapies to address addiction and mental illness. The firm's commercial drug development programs includes lysergic acid diethylamide (LSD) experiential therapy, 18-methoxycoronaridine (18-MC) opioid withdrawal, LSD microdosing, methylenedioxymethamphetamine (MDMA), and dimethyltryptamine (DMT). The firm's subsidiaries include Mind Medicine, Inc., HealthMode, Inc., MindMed Pty Ltd. and MindMed GmbH.
See Also
What is Mind Medicine (MindMed) Inc's Common Shares Outstanding?
Common Shares Outstanding
76.8m
USD
Based on the financial report for Sep 30, 2025, Mind Medicine (MindMed) Inc's Common Shares Outstanding amounts to 76.8m USD.
What is Mind Medicine (MindMed) Inc's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 10Y
23%
Over the last year, the Common Shares Outstanding growth was -6%. The average annual Common Shares Outstanding growth rates for Mind Medicine (MindMed) Inc have been 27% over the past three years , 38% over the past five years , and 23% over the past ten years .
